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uncomplicated bone metastases. Actually, no evidence based 
recommendations are available for the treatment of 
complicated bone metastases. This study was conducted to 
evaluate the effectiveness in term of symptom control of a 
SHort course Accelerated RadiatiON therapy (SHARON study) 
in the treatment of patients with complicated bone 
metastases. 
Materials and Methods: A phase II clinical trial was designed. 
Patients with complicated bone metastases metastases, and 
Eastern Cooperative Oncology Group (ECOG) performance 
status < 3 were included. Treatment was delivered in two 
days with a twice daily fractionation and at least an eight 
hour interval at 20 Gy (5 Gy per fraction). The primary 
endpoint was the assessment of efficacy in terms of pain 
relief. 
Results: Characteristics of the 25 enrolled patients were: 
male/female: 14/11; median age: 65 years (range, 45 to 85 
y). The site of the primary tumor was: lung (36%), breast 
(32%), prostate (12%), kidney (8%), rectum (4%), thyroid (4%), 
and uterus (4%). All patients had pain at the time of 
treatment. Three weeks after treatment, the response of 
pain was evaluated by visual analogue scale (VAS). 23 of the 
25 symptomatic patients had improvement or resolution of 
pain based (overall response rate to the symptom: 92.5% CI 
0.95: 68.68% - 99.13). Specifically, 8 patients (32%) had 
complete resolution of pain, 15 patients (60%) had a partial 
response and 2 patients (8%) remained stable. A statistically 
significant reduction in pain assessed by VAS, was recorded 
(pre-treatment vs. post-treatment mean VAS = 5.9±2.6 vs. 
2.7±2.5; p = 0.039). Only 1 patient required retreatment at 
12 months. In addition, 18 of the 25 patients (72%) showed 
improvement or stability ECOG. Only acute toxicities of grade 
1 and 2 were recorded: skin G1 =16%, hematological (anemia) 
G1 = 4%, gastro-intestinal G1 (diarrhea) = 4%, gastrointestinal 
(nausea and vomiting) G2 =8%. 
Conclusions: Short course accelerated radiotherapy of 20 Gy 
BID in two consecutive days is effective in term of symptoms 
relief. These results justify a phase III comparison against the 
standard-of-care in these patients’ population (30 Gy in 10 
fractions). 
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Purpose/Objective: Recent technology of diagnosis has 
increased prevalence of oligometastatic patients. 
Stereotactic body radiotherapy (SBRT) to oliogometastases 
showed outstanding local control but also promising overall 
survival. Though liver oliogmetastses is a most common site 
for surgery, above 70% of these patients are unresectable. An 
effective and safe local modality option is necessary for 
these patients. We analyzed outcomes and toxicity for 
patients with liver oligometastases treated by SBRT from 
variable tumors. 
Materials and Methods: Seventy-two patients with liver 
oligometastases from 2002 to 2013 were treated by SBRT 
consecutively. Among them, 17 patients excluded; un-
controllable distant metastases in 9 patients and immediate 
follow-up loss after treatment in 8 patients. A total of 55 
patients with 77 lesions were analyzed retrospectively. 
Primary lesion of all patients was controlled, the patients 
with stable lesions in another site in 28 patients. The most 
common primary organ was colon in 36 patients followed by 
the stomach 6 patients, and other 13 patients. The tumor 
volume was calculated by sum of total GTV. The median 
volume was 20 cc (0.7-721.2 cc). Thirty-eight (69%) of the 
patients had a single metastatic lesion. Total SBRT dose was 
from 30 to 60 Gy (median 48 Gy) by 3-4 fractions. Thirty-nine 
(72%) of the patients received chemotherapy as part of their 
primary treatment. Toxicity was evaluated by Common 
Toxicity Criteria for Adverse Events Version 4.0 Grading 
scale. 
Results: The 2 and 5-year overall survival rate was 56% and 
20%, respectively. Actuarial 2 year local control and 
progression free survival rate were 60% and 22%, 
respectively. Grade 1-2 fatigue, nausea, and vomiting were 
the most common adverse events, and no grade 3 and higher 
adverse events were observed. By multivariate analysis 
according to survival, other visible lesion was a statistically 
significant factor. 
Conclusions: SBRT for liver oligometastases seems to be safe. 
High SBRT dose is correlated with high local control. To 
obtain survival gain through SBRT among patients with 
oligorecurrence, criteria of optimal candidate is mandatory. 
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Purpose/Objective: 8 Gy single fraction (flash) conventional 
external beam radiation therapy is the most commonly 
administered single fraction dose and is considered the 
standard treatment for uncomplicated bone metastases. 
However, its efficacy is uncertain in patients with bone 
metastases involving the adjacent soft tissues. Aim of the 
study was to evaluate the flash efficacy in terms of pain 
control for this particular patient setting. 
Materials and Methods: An observational study of patients 
treated with Radiotherapy for bone metastases was 
conducted from January 2003 to December 2010 in our 
Department. The study included patients with painful bone 
metastases of any primary sites and any ECOG performance 
status < 4. Eight Gray single fraction conventional external 
beam radiation therapy (3DCRT) was administered. Patients 
were evaluated for pain with visual-analogue scale (VAS) 
before and 3 weeks after irradiation. Pain response was 
